These factors may induce DNA damage, epigenetic changes and cancer-related mutations, leading to the silencing of tumor suppressors (such as TP53, CDH1, RASSF1) and the activation of oncogenes (such as MYC, VEGFA, MAPK7), which ultimately contribute to the progression of HCC [5]. This evidence concerns the gene TP53 and hepatocellular carcinoma.